Isolation of CF cell lines corrected at ΔF508-CFTR locus by SFHR-mediated targeting

被引:130
作者
Bruscia, E
Sangiuolo, F
Sinibaldi, P
Goncz, KK
Novelli, G
Gruenert, DC
机构
[1] Univ Vermont, Dept Med, Hlth Sci Res Facil, Burlington, VT 05405 USA
[2] Univ Roma Tor Vergata, Dept Biopathol & Diagnost Imaging, Rome, Italy
[3] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy
关键词
gene targeting; small fragment homologous replacement (SFHR); CFTR;
D O I
10.1038/sj.gt.3301741
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cystic fibrosis is the most common inherited disease in the Caucasian population. About 70% of all CF chromosomes carry the DeltaF508 mutation, a 3-bp deletion that results in the loss of a phenylalanine at amino acid 508 in the CF transmembrane conductance regulator (CFTR) protein. Direct modification of the DeltaF508 locus of endogenous CFTR was achieved by small fragment homologous replacement (SFHR), Transformed human airway epithelial cells (CFBE41o(-)), homozygous for DeltaF508 mutation, were transfected with small fragments (491-bp) of wild-type (WT) CFTR DNA comprising exon 10 and the flanking introns. The DNA fragments were in a liposome-DNA complex at a charge ratio of 6:1 (+:-), respectively). The population of transfected cells was subcloned by limiting dilution at similar to1 cell/well in 96-well plates. Individual colonies were isolated and analyzed. The DNA from several colonies was characterized by radiolabeled, nonallele-specific and radiolabeled, allele-specific PCR amplification, as well as by genomic DNA fingerprinting. The CFTR-WT allele was detected in five of these colonies by allele-specific PCR amplification thus indicating that the cell lines carried both WT and DeltaF alleles. DNA fingerprint analysis confirmed that the colonies were isogenic and derived from the parental CFBE41o(-) cell line. Although, the WT allele was detected by allele-specific PCR, it was not detected initially when the same samples were analyzed by non allele-specific PCR. A sensitivity assay, mixing the genomic DNA of wild-type (16HBE14o(-)) and mutant (CFBE41o(-)) cell lines, indicated that the allele-specific PCR was at least 25-fold more sensitive than nonallele-specific PCR. These results suggest that the colony is not yet clonal, but still contains a population of parental, CFBE41o(-) cells that have not been modified. Based on the mixing analysis, the proportion of corrected cells appears to be between 1 and 10% of the total population. Nonallele-specific reverse transcriptase PCR (RT-PCR) analysis of the CFTR mRNA indicated that two of the colonies expressed both WT and DeltaF508 CFTR mRNA, while one colony appeared to express only the WT mRNA. The mRNA results were confirmed by sequence analysis of 3' end primer extension products from the mRNA of CFTR exon 10 showing that the mRNA containing exon 10. Furthermore, a survey of primer extension products indicated no random insertion of the fragment in an expressed gene. This study demonstrates SFHR-mediated modification of the DeltaF508 allele in DeltaF508 homozygote human airway epithelial cells over multiple generations. The resultant cells express WT-CFTR mRNA and can be subcloned further to isolate isogenic clonal populations of cells.
引用
收藏
页码:683 / 685
页数:3
相关论文
共 7 条
  • [1] Targeted replacement of normal and mutant CFTR sequences in human airway epithelial cells using DNA fragments
    Goncz, KK
    Kunzelmann, K
    Xu, ZD
    Gruenert, DC
    [J]. HUMAN MOLECULAR GENETICS, 1998, 7 (12) : 1913 - 1919
  • [2] Expression of ΔF508 CFTR in normal mouse lung after site-specific modification of CFTR sequences by SFHR
    Goncz, KK
    Colosimo, A
    Dallapiccola, B
    Gagné, L
    Hong, K
    Novelli, G
    Papahadjopoulos, D
    Sawa, T
    Schreier, H
    Wiener-Kronish, J
    Xu, Z
    Gruenert, DC
    [J]. GENE THERAPY, 2001, 8 (12) : 961 - 965
  • [3] Opportunities and challenges in targeting genes for therapy
    Gruenert, DC
    [J]. GENE THERAPY, 1999, 6 (08) : 1347 - 1348
  • [4] Gruenert DC, 1998, CURR RES MOL THER, V1, P607
  • [5] In vivo and in vitro correction of the mdx dystrophin gene nonsense mutation by short-fragment homologous replacement
    Kapsa, R
    Quigley, A
    Lynch, GS
    Steeper, K
    Kornberg, AJ
    Gregorevic, P
    Austin, L
    Byrne, E
    [J]. HUMAN GENE THERAPY, 2001, 12 (06) : 629 - 642
  • [6] Kunzelmann K, 1996, GENE THER, V3, P859
  • [7] SANGIUOLO F, 2001, PED PULMON S, V20, P240